瑞贝克联合治疗十二指肠溃疡的临床研究

Clinical Study of Therapeutic Alliance with Swibec in Treatment of Duodenal Ulcer

目的探讨瑞贝克联合治疗幽门螺杆菌(Hp)阳性十二指肠溃疡的疗效。方法将98例Hp阳性的十二指肠溃疡患者随机分为两组:治疗组(55例)使用奥美拉唑、瑞贝克和阿莫西林治疗;对照组(43例),使用奥美拉唑,甲硝唑和阿莫西林进行治疗。观察临床症状,十二指肠溃疡愈合情况,Hp的清除率和不良反应。结果治疗组的症状缓解率和溃疡愈合率分别为94.55%和89.09%,较对照组81.40%和79.07%,明显提高,差异有统计学意义(P<0.05);而治疗组Hp根除率为90.09%,较对照组81.39%有升高的趋势,但差异无统计学意义(P>0.05)。两组不良反应相比,差异均无统计学意义(P>0.05)。结论奥美拉唑、瑞贝克和阿莫西林三联疗法对治疗Hp感染的十二指肠溃疡有较好的疗效,尤其值得临床推广的治疗方法之一。

Objective To explore the curative effect of therapeutic alliance with omeprazole, swibec and amoxicillin for helieobaeter pylori positive duodenal ulcer. Methods 98 cases with Hp positive duodenal ulcer were randomly divided into two groups. The treatment group（ n = 55 ） was treated with omeprazole, swibec and amoxicillin, while the control group（ n = 43 ） was treated with omeprazole, metronidazole and amoxicillin. The remission rate of symptom, rate of ulcer cicatrization, eradication rate of Hp and adverse events were observed in each group. Results At the end of the treatment program,the remission rate of symptom and rate of ulcer cicatrization in treatment group was 94.55% and 89.09% respectively, and that of the control group was 81.40% and 79.07% （P 〈 0.05 ） , while there was no significant difference in the eradication rate of Hp and the adverse effect incidence between two groups（ P 〉0.05 ）. There was increased tendency of the eradication rate of Hp in treatment than that in control group. Conclusion Therapeutic alliance with omeprazole, swibec and amoxieillin was safe, and effective for H. Pylori positive duodenal ulcer. It was a worthy method for clinic.